Cargando…
Combining variant detection and fragment length analysis improves detection of minimal residual disease in postsurgery circulating tumour DNA of stage II–IIIA NSCLC patients
Stage II–IIIA nonsmall cell lung cancer (NSCLC) patients receive adjuvant chemotherapy after surgery as standard‐of‐care treatment, even though only approximately 5.8% of patients will benefit. Identifying patients with minimal residual disease (MRD) after surgery using tissue‐informed testing of po...
Autores principales: | Vessies, Daan C. L., Schuurbiers, Milou M. F., van der Noort, Vincent, Schouten, Irene, Linders, Theodora C., Lanfermeijer, Mirthe, Ramkisoensing, Kalpana L., Hartemink, Koen J., Monkhorst, Kim, van den Heuvel, Michel M., van den Broek, Daan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9297781/ https://www.ncbi.nlm.nih.gov/pubmed/35674097 http://dx.doi.org/10.1002/1878-0261.13267 |
Ejemplares similares
-
Cell-Free DNA at Diagnosis for Stage IV Non-Small Cell Lung Cancer: Costs, Time to Diagnosis and Clinical Relevance
por: Koole, Simone N., et al.
Publicado: (2022) -
Biological and technical factors in the assessment of blood-based tumor mutational burden (bTMB) in patients with NSCLC
por: Schuurbiers, Milou, et al.
Publicado: (2022) -
Cell-free DNA in the supernatant of pleural effusion can be used to detect driver and resistance mutations, and can guide tyrosine kinase inhibitor treatment decisions
por: Hummelink, Karlijn, et al.
Publicado: (2019) -
Clinical Utility of Plasma-Based Comprehensive Molecular Profiling in
Advanced Non–Small-Cell Lung Cancer
por: Schouten, Robert D., et al.
Publicado: (2021) -
Performance of four platforms for KRAS mutation detection in plasma cell-free DNA: ddPCR, Idylla, COBAS z480 and BEAMing
por: Vessies, D. C. L., et al.
Publicado: (2020)